Physician profile
Barry Menna
NPI 1568442390
$3,274.83
in general payments reported to CMS, 2019-2025
36 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $136 · 2021: $416 · 2022: $610 · 2023: $430 · 2024: $792 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $795.24 | 2021-2025 | |
| Pfizer INC. | $216.62 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $196.18 | 2019-2024 | Austedo Xr, Austedo |
| Lilly USA, LLC | $177.47 | 2021-2024 | Emgality, Reyvow, Amyvid |
| Novartis Pharmaceuticals Corporation | $168.22 | 2019-2024 | |
| Emd Serono, INC. | $140.67 | 2019-2022 | |
| Ucb, INC. | $139.51 | 2019-2024 | Briviact |
| Biogen, INC. | $126.29 | 2019-2022 | |
| Allergan, INC. | $120.78 | 2019-2021 | |
| Mdd US Operations, LLC | $114.25 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $106.95 | 2019-2022 | |
| Livanova USA, INC. | $90.60 | 2021-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $89.11 | 2019-2024 | Nuplazid |
| Amneal Pharmaceuticals LLC | $73.62 | 2019-2024 | Rytary |
| Medtronic, INC. | $70.30 | 2025 | Linq II |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $69.42 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $65.27 | 2022 | |
| Genentech USA, INC. | $57.50 | 2019 | |
| Eisai INC. | $44.46 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $43.56 | 2019 | |
| Sk Life Science, INC. | $42.88 | 2022 | |
| Amgen INC. | $34.70 | 2019 | |
| Avanir Pharmaceuticals, INC. | $34.29 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $33.67 | 2021 | |
| Assertio Therapeutics, INC. | $27.12 | 2019-2020 | |
| Genzyme Corporation | $24.12 | 2019 | |
| Tanabe Pharma America, INC. | $23.75 | 2024 | |
| Janssen Pharmaceuticals, INC | $21.60 | 2022 | |
| Neurelis, INC. | $21.41 | 2024 | Valtoco |
| Csl Behring | $17.47 | 2019 | |
| Adamas Pharmaceuticals, INC. | $16.84 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.56 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.54 | 2024 | Nuedexta |
| Alnylam Pharmaceuticals INC. | $14.83 | 2019 | |
| Sumitomo Pharma America, INC. | $12.29 | 2023 | Aptiom |
| Lundbeck LLC | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Menna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.